- Investors & Media
- Investors & Media
- Contact Us
Kamada announced that over dozens of patients with alpha-1 antitrypsin deficiency have already begun treatment of inhaled AAT beyond the time frame of the Phase II/III clinical trial; Kamada estimates that dozens of additional patients are expected to apply for continuation of treatment
This year, the company will complete its phase 2/3 clinical trial in Europe to treat AAT deficiency, it will start a phase 2 clinical trial in the US with the same product, and it expects to start a Phase 2 or phase 2/3 clinical trial to treat newly diagnosed type-1 Diabetes.
Kamada reports continued revenue growth, primarily due to an increase in the sale of the GLASSIA drug in the USA, and that it has crossed the threshold to operational profitability and achieved net annual profit. Kamada’s net profit in Q4 of 2012 was about $3 million. The company showed progress in the development of the indications for the inhaled AAT for treatment of Alpha-1 Antitrypsin Deficiency (AATD) and AAT for newly diagnosed Type-1 diabetes.
As Kamada's chairman Hahn founded and led Kamada from an idea to becoming a groundbreaking, leading company in its field of development, manufacture and marketing of specialty lifesaving biopharmaceuticals.
The Australian Patent Registrar has granted the Company a patent for inhaled Alpha-1 Antitrypsin.
The award was given based on the success of the Company's strategy in selling GLASSIA in the U.S. and worldwide, transforming it to an export-oriented company. The Company's exports in the first nine months of 2012 grew to $27.5 million
Kamada is the most advanced company in development of inhaled AAT drug for including for the treatment of CF.The previous phase II clinical trial showed an excellent safety and tolerability profile in addition to positive efficacy results indicating a substantial decrease in lung inflammation.
Drug developer Kamada Ltd. (TASE: KMDA) today announced that it has been included in the Deloitte Technology Fast 500 EMEA 2012. The list includes the 500 fastest-growing technology, media, telecommunications, life sciences, and cleantech companies in Europe, the Middle East, and Africa.
Kamada is among the fastest growing companies in Europe according to the Deloitte Technology Fast 500™ index for the year 2012. The list includes the 500 fastest growing companies in Europe, the Middle East and Africa (EMEA) in the fields of technology, media, communications, life sciences and cleantech.
The Company has announced that it is examining the possibility of a public offering of its ordinary shares in the United States and the listing thereof on a U.S. stock…